
OPCH Stock Forecast & Price Target
OPCH Analyst Ratings
Bulls say
Option Care Health is poised for strong financial performance in the upcoming years, driven by a de-risked product portfolio and partnerships with healthcare providers and payors. The company has exceeded analyst expectations for adjusted EPS and adjusted EBITDA in the first quarter, and its management has maintained their guidance for these metrics for FY/26. Additionally, Option Care's expected 4% revenue growth in FY/26 is expected to be driven by its collaboration with healthcare professionals and commitment to providing cost-effective care. These factors, along with the potential for a strong stock performance, have led to a positive outlook on the company's stock.
Bears say
Option Care Health is facing several headwinds that are expected to impact its revenue and gross profit, with a particularly negative impact from changes in the insurance landscape for autoimmune and chronic inflammatory disorders. Additionally, slower growth for certain specialty therapies and launch delays for rare and orphan products are expected to further hinder growth. While management remains confident in its ability to improve margins, there are risks to growth and competition in the infusion market that could weigh on profitability. Additionally, the company's exposure to Stelara is expected to significantly decrease in the future, providing some stabilization. Overall, while there are some positive aspects to the company's performance, the negative factors outweigh them, leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Option Care Health and is not a guaranteed prediction by Public.com or investment advice.
OPCH Analyst Forecast & Price Prediction
Start investing in OPCH
Order type
Buy in
Order amount
Est. shares
0 shares